Riskpilot← Back to searchSign inGet full accessModus Therapeutics AB
ABActiveOrg 5566692199Sankt Eriksgatan 117Research and experimental development on natural sciences and engineering · NACE 7210Est. 20040 employees
Revenue 2024
SEK 0
EBITDA margin
—
+1% vs 2023
Equity ratio
90.6%
Financial strength
Net profit 2024
SEK -577K
+79% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -9M | +1% |
| Net profit | SEK -577K | +79% |
| Total assets | SEK 16,5M | +3% |
| Equity | SEK 15M | -4% |
| Employees | 0 | — |
Legal name
Modus Therapeutics AB
Org number
5566692199
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26 oktober 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av ledamöterna i förening med suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva forskning-, utveckling-, försäljning- och licensieringsverksamhet inom läkemedelsområdet samt därmed förenlig verksamhet.
Address
Sankt Eriksgatan 117
Email
john.ohd@modustx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 27 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −22 550 | −20 350 | −38 001 | −49 215 | −38 510 | −3 879 | −14 166 | −11 674 | −9 134 | −9 018 |
| Depreciation & amort. | −566 | −323 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −23 116 | −20 673 | −38 001 | −49 215 | −38 510 | −3 879 | −14 166 | −11 674 | −9 134 | −9 018 |
| Net financials | −1 | 1 | −1 | — | — | 2 | — | — | 1 | 1 |
| Profit before tax | −23 117 | −20 673 | −38 002 | −49 215 | −38 510 | −3 877 | 11 034 | 6 226 | −2 709 | −577 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −23 117 | −20 673 | −38 002 | −49 215 | −38 510 | −3 877 | 11 034 | 6 226 | −2 709 | −577 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4 217 | 13 387 | 19 263 | 31 299 | 3 165 | 1 012 | 16 344 | 19 446 | 16 049 | 16 518 |
| Equity | 1 544 | 2 971 | 3 469 | 10 254 | 1 743 | 866 | 12 026 | 18 253 | 15 543 | 14 967 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 673 | 10 416 | 15 794 | 21 045 | 1 421 | 145 | 4 318 | 1 193 | 506 | 1 551 |
| Total debt | 2 673 | 10 416 | 15 794 | 21 045 | 1 421 | 145 | 4 318 | 1 193 | 506 | 1 551 |
EBITDA margin
-901800000.0%
This company
15.8%
Market median
-5707595037% vs market
20152024
Equity ratio
90.6%
This company
38.2%
Market median
+137% vs market
20152024
Return on equity
-3.9%
This company
18.4%
Market median
-121% vs market
20152024
Net profit margin
-57700000.0%
This company
8.1%
Market median
-712345779% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EO Chief Auditor | Chief Auditor | 2020 | — | — |
EK Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
JF Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
LM Chief Auditor | Chief Auditor | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Modus Therapeutics Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KDventures AB
Modus Therapeutics AB Board members of Modus Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Oskar Wall | Chief Auditor | 0 companies |
| Ellen Kinson Donnelly | Chief Executive Officer | 0 companies |
| John Fredrik Öhd | Chief Executive Officer | 0 companies |
| Linn Maria Haslum Lindgren | Chief Auditor | 0 companies |
| Viktor Drvota | Chairman | 0 companies |
| Stig Løkke Pedersen | Chairman | 0 companies |
| Johan Ulf Niclas Dighed | Deputy Board Member | 0 companies |